Health Technology · Pharmaceuticals: Major · NSE: EMCURE · data 2026-10-09
Emcure Pharmaceuticals Limited
Health check: Strong (8.4/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹1,833.5
Market cap
₹35,120 cr
P/E
34.4
P/B
—
ROE
19.7%
ROCE
22.6%
Debt / equity
0.31
Dividend yield
0.19%
1-year return
33.0%
52-week high
₹2,100.7
52-week low
₹1,306.5
Operating margin
15.2%
Growth
| Revenue (last 12 months) | ₹9,683 cr |
| Net profit (last 12 months) | ₹1,011 cr |
| Sales growth, 3 years (yearly) | 15.4% |
| Profit growth, 3 years (yearly) | 20.2% |
Chart patterns
- Double top — forming (key level ₹1,830.1)
Similar companies
Ajanta Pharma Limited (AJANTPHARM) · GlaxoSmithKline Pharmaceuticals Limited (GLAXO) · Wockhardt Limited (WOCKPHARMA) · Neuland Laboratories Ltd. (NEULANDLAB) · Piramal Pharma Limited (PPLPHARMA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open EMCURE in NSE Scanner →